The content on this site is intended for healthcare professionals only
EBCC 2014 Satellite Symposium supported by GSK: 'Heading in the right direction? Optimal sequencing pathways for HER2-positive metastatic breast cancer'
Prof Bartsch talks through the options available for HER2-positive metastatic breast cancer for a certain case study.
To view the slides fullscreen click the square and arrows button at the bottom right of the player.
GSK has paid for the organisational costs of the symposium, and honoraria for the chairperson and speakers. GSK has contributed to the agenda and content of this meeting.
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
The advantages of IORT for early breast cancer treatment
The pros and cons of breast IORT and ultra hypofractionation (FR)
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
IORT at the Asian Hospital and Medical Center
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer
